Great Point Partners (GPP) has completed a growth investment in iXCells Biotechnologies, according to a news release.
iXCells, based in San Diego, is a provider of cell-based products and discovery services to the academic, biotech and pharmaceutical communities worldwide. Founded in 2014, the company focuses on primary and induced pluripotent stem cell-derived cellular models.
GPP, based in Greenwich, Conn., is a private investment firm focused on the healthcare industry. Founded in 2003, the firm targets investments in biopharmaceutical supply chain services and products; healthcare services; healthcare information technology-enabled services; and medical devices and diagnostics in businesses operating in the United States, Canada and Western Europe. GPP pursues companies generating between $10 million and $100 million of revenue and $2 million to $12 million of EBITDA, with equity investments ranging from $7 million to $50 million.
Terms of the investment were not disclosed.